Filed Jan. 29, 2026

Serial No. 99622513

Examining Attorney JONATHON A SCHLEGELMILCH

Class pharmaceuticals for the treatment of neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), cancer, and obesity; pharmaceuticals for the treatment of life-threatening diseases; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics for use in the treatment of neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), cancer, and obesity; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics that feature RNA as their active ingredient; pharmaceuticals, namely, small molecule therapeutics that induce changes in the chemical modifications of ribonucleic acid (RNA); pharmaceuticals, namely, viral vector therapeutics that induce changes in the chemical modifications of ribonucleic acid (RNA); 005; 006; 018; 044; 046; 051; 052; 100; 103; 106; 100; 101; 100; 101

Case Type Trademark Service mark